Bin Ma, PhD, Associate Professor. He obtained his Bachelor's degree in Biological Sciences in 2005 at Lanzhou University, China, and his Master's degree in Medical Pharmaceutical Sciences with honor (cum laude) in 2007 at University of Groningen, The Netherlands. In 2012, Bin Ma completed his PhD at University of Twente, The Netherlands, and won the 2011 Chinese Government Award for Outstanding Self-financed Students Abroad. From 2013 to 2015, he performed his postdoctoral research at University of Zurich and University Children's Hospital Zurich, Switzerland. In October 2015, Dr. Ma joined the School of Biomedical Engineering, Shanghai Jiao Tong University. In 2016, he won the title of Shanghai Young Eastern Scholar.
– 2012 University of Twente, The Netherlands. Ph.D. (Cell and Molecular Biology)
– 2007 University of Groningen, The Netherlands. M.Sc. cum laude (Medical Pharmaceutical Sciences)
– 2005 Lanzhou University, China. B.Sc. (Biology)
2016 till now School of Biomedical Engineering, Shanghai Jiao Tong University, China. Assistant Professor
2014 – 2015 Division of Immunology, University Children's Hospital Zurich,
Switzerland. Post-doctoral researcher
– 2014 Institute of Veterinary Biochemistry and Molecular Biology, University
of Zurich, Switzerland. Post-doctoral researcher
Oncogenic pathways and tumor microenvironment, tumor intrinsic mechanisms for immune escape, cancer immunotherapy.
Yekehfallah V, Pahlavanneshan S, Sayadmanesh A, Momtahan
Z, Ma B*, Basiri M*. Generation and functional characterization of PLAP
CAR-T cells against cervical cancer cells. Biomolecules 2022; 12: 1296. *Corresponding author
Ji L, Peng P, Gui L, Yuan P, Qian W, Wang Y, Gao WQ*, Ma B*. CD24 is a superior immunotherapeutic target to PD-1 in a mouse model of Helicobacter-induced gastric cancer. Gastro Hep Advances 2022; 1(1):79-82. *Corresponding author
Yan J, Yuan P, Gui L, Wang Z, Yin P, Gao WQ, Ma B*. CCL28 downregulation attenuates pancreatic cancer progression through tumor cell-intrinsic and -extrinsic mechanisms. Technol Cancer Res Treat 2021; 20:15330338211068958. *Corresponding author
Wang C#, Yan J#, Yin P, Gui L, Ji L, Ma B*, Gao WQ*. β-Catenin inhibition shapes tumor immunity and synergizes with immunotherapy in colorectal cancer. OncoImmunology 2020; 9(1): e1809947. #Co-first author; *Corresponding author
Yin P, Gui L, Wang C, Yan J, Liu M, Ji L, Wang Y, Ma B*, Gao WQ*. Targeted delivery of CXCL9 and OX40L by mesenchymal stem cells elicits potent antitumor immunity. Mol Ther 2020; 28(12):2553-63. *Corresponding author
Ji L, Qian W, Gui L, Ji Z, Yin P, Lin GN, Wang Y, Ma B*, Gao WQ*. Blockade of β-catenin-induced CCL28 suppresses gastric cancer progression via inhibition of Treg cell infiltration. Cancer Res 2020; 80(10):2004-16. *Corresponding author
Ma B, Hottiger MO. Crosstalk between Wnt/β-catenin and NF-κB signaling during inflammation. Front Immunol 2016; 7:378.
Ma B, Fey M, Hottiger MO. WNT/β-catenin signaling inhibits CBP-mediated RelA acetylation and expression of a proinflammatory subset of NF-κB target genes. J Cell Sci 2015; 128:2430-2436.
Ma B, Zhong L, van Blitterswijk CA, Post JN, Karperien M. T cell factor 4 is a pro-catabolic and apoptotic factor in human articular chondrocytes by potentiating nuclear factor κB signaling. J Biol Chem 2013; 288:17552-8.
Ma B, van Blitterswijk CA, Karperien M. A Wnt/β-catenin negative feedback loop inhibits interleukin-1-induced matrix metalloproteinase expression in human articular chondrocytes. Arthritis Rheum 2012; 64:2589-600.
Ter Elst A*, Ma B*, Scherpen FJG, de Jonge HJ, Douwes J, Wierenga AT, Schuringa JJ, Kamps WA, de Bont ES. Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia. Cancer Res 2011; 71:2761-71. *Co-first author
The Basics of Immune Diseases and Cancer Immunology (Graduate)